Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Talecris Biotherapeutics has introduced Prolastin-C (Alpha1-Proteinase Inhibitor [Human])(A1PI) in Canada.
Subscribe to our email newsletter
Talecris Biotherapeutics claims that Prolastin-C is more concentrated and purified formulation of Prolastin, the only approved alpha1-augmentation therapy in Canada.
Prolastin-C and Prolastin are indicated for chronic augmentation and maintenance therapy in adults who have emphysema due to a genetic condition known as alpha1-antitrypsin (AAT) deficiency.
Talecris Portfolio Management & International Business senior vice president & general manager Joel Abelson said that Talecris research and development scientists continually strive to enhance the overall quality of the products by incorporating the latest advances in technology.